See more : Taisei Oncho Co., Ltd. (1904.T) Income Statement Analysis – Financial Results
Complete financial analysis of PolyPeptide Group AG (PPGN.SW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PolyPeptide Group AG, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- China Merchants Securities Co., Ltd. (6099.HK) Income Statement Analysis – Financial Results
- Saudi Industrial Services Company (2190.SR) Income Statement Analysis – Financial Results
- MEDIA DO Co., Ltd. (MDDCF) Income Statement Analysis – Financial Results
- Oriental Aromatics Limited (OAL.NS) Income Statement Analysis – Financial Results
- NEXTAGE Co., Ltd. (3186.T) Income Statement Analysis – Financial Results
PolyPeptide Group AG (PPGN.SW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.polypeptide.com
About PolyPeptide Group AG
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 320.37M | 280.98M | 282.13M | 224.30M | 202.61M | 179.57M |
| Cost of Revenue | 315.73M | 228.99M | 182.43M | 151.11M | 131.04M | 117.45M |
| Gross Profit | 4.64M | 51.99M | 99.70M | 73.19M | 71.57M | 62.12M |
| Gross Profit Ratio | 1.45% | 18.50% | 35.34% | 32.63% | 35.33% | 34.60% |
| Research & Development | 1.47M | 1.24M | 1.41M | 1.31M | 14.38M | 12.31M |
| General & Administrative | 17.18M | 34.54M | 27.58M | 23.76M | 9.07M | 8.68M |
| Selling & Marketing | 1.58M | 4.91M | 3.86M | 3.64M | 1.24M | 1.31M |
| SG&A | 18.76M | 40.63M | 32.50M | 28.01M | 10.31M | 9.99M |
| Other Expenses | 20.89M | 0.00 | 0.00 | 0.00 | 13.34M | 12.07M |
| Operating Expenses | 41.11M | 42.34M | 37.04M | 32.29M | 38.03M | 34.36M |
| Cost & Expenses | 356.84M | 271.33M | 219.46M | 183.40M | 169.06M | 151.81M |
| Interest Income | 54.00K | 2.08M | 2.82M | 3.21M | 70.00K | 78.00K |
| Interest Expense | 5.62M | 2.09M | 2.82M | 3.32M | 3.24M | 4.12M |
| Depreciation & Amortization | 30.47M | 26.06M | 20.68M | 17.55M | 15.81M | 14.42M |
| EBITDA | -22.15M | 35.72M | 83.35M | 58.55M | 49.28M | 42.59M |
| EBITDA Ratio | -6.91% | 11.76% | 29.58% | 26.05% | 24.38% | 23.72% |
| Operating Income | -36.47M | 12.53M | 67.40M | 44.31M | 33.55M | 27.76M |
| Operating Income Ratio | -11.38% | 4.46% | 23.89% | 19.76% | 16.56% | 15.46% |
| Total Other Income/Expenses | -21.78M | -5.04M | -4.32M | -6.69M | -3.32M | 1.69M |
| Income Before Tax | -58.24M | 7.57M | 59.85M | 37.69M | 30.23M | 29.45M |
| Income Before Tax Ratio | -18.18% | 2.69% | 21.21% | 16.80% | 14.92% | 16.40% |
| Income Tax Expense | -6.80M | 200.00K | 12.59M | 6.35M | 4.50M | 5.63M |
| Net Income | -51.44M | 7.77M | 47.26M | 31.34M | 25.74M | 23.82M |
| Net Income Ratio | -16.06% | 2.76% | 16.75% | 13.97% | 12.70% | 13.26% |
| EPS | -1.56 | 0.24 | 1.47 | 1.04 | 0.86 | 0.79 |
| EPS Diluted | -1.56 | 0.24 | 1.47 | 1.04 | 0.86 | 0.79 |
| Weighted Avg Shares Out | 32.94M | 32.99M | 32.10M | 30.00M | 30.00M | 30.00M |
| Weighted Avg Shares Out (Dil) | 32.97M | 33.00M | 32.12M | 30.00M | 30.00M | 30.00M |
Source: https://incomestatements.info
Category: Stock Reports